Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone206-838-0500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.07 million
Profitability
Miscellaneous
Employees118
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable
Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions
What is Aptevo Therapeutics' stock symbol?
Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."
How were Aptevo Therapeutics' earnings last quarter?
Aptevo Therapeutics Inc (NASDAQ:APVO) issued its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03. The biotechnology company had revenue of $7.36 million for the quarter, compared to analyst estimates of $6.95 million. Aptevo Therapeutics had a negative return on equity of 148.97% and a negative net margin of 195.98%. View Aptevo Therapeutics' Earnings History.
When is Aptevo Therapeutics' next earnings date?
What price target have analysts set for APVO?
3 equities research analysts have issued 1 year price objectives for Aptevo Therapeutics' stock. Their predictions range from $3.00 to $14.00. On average, they anticipate Aptevo Therapeutics' share price to reach $9.67 in the next year. This suggests a possible upside of 1,371.6% from the stock's current price. View Analyst Price Targets for Aptevo Therapeutics.
What is the consensus analysts' recommendation for Aptevo Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aptevo Therapeutics.
Has Aptevo Therapeutics been receiving favorable news coverage?
News articles about APVO stock have trended somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptevo Therapeutics earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Aptevo Therapeutics.
Are investors shorting Aptevo Therapeutics?
Aptevo Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,250,000 shares, an increase of 23.8% from the August 30th total of 1,010,000 shares. Based on an average daily volume of 526,000 shares, the short-interest ratio is presently 2.4 days. Currently, 3.1% of the company's stock are short sold. View Aptevo Therapeutics' Current Options Chain.
Who are some of Aptevo Therapeutics' key competitors?
Some companies that are related to Aptevo Therapeutics include IDEAYA Biosciences (IDYA), CytoDyn (CYDY), Paratek Pharmaceuticals (PRTK), Abeona Therapeutics (ABEO), Adamas Pharmaceuticals (ADMS), Helix Biopharma (HBPCF), Scpharmaceuticals (SCPH), Fulcrum Therapeutics (FULC), Eton Pharmaceuticals (ETON), Aptinyx (APTX), Strongbridge Biopharma (SBBP), Correvio Pharma (CORV), Chembio Diagnostics (CEMI), Corvus Pharmaceuticals (CRVS) and Processa Pharmaceuticals (PCSA).
What other stocks do shareholders of Aptevo Therapeutics own?
Who are Aptevo Therapeutics' key executives?
Aptevo Therapeutics' management team includes the folowing people:
- Mr. Marvin L. White, Pres, CEO & Director (Age 57)
- Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 53)
- Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 61)
- Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 58)
- Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 62)
How do I buy shares of Aptevo Therapeutics?
Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aptevo Therapeutics' stock price today?
One share of APVO stock can currently be purchased for approximately $0.66.
How big of a company is Aptevo Therapeutics?
Aptevo Therapeutics has a market capitalization of $29.63 million and generates $23.07 million in revenue each year. The biotechnology company earns $-53,690,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.View Additional Information About Aptevo Therapeutics.
What is Aptevo Therapeutics' official website?
How can I contact Aptevo Therapeutics?
Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]
MarketBeat Community Rating for Aptevo Therapeutics (NASDAQ APVO)
MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote "Outperform" if you believe APVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
